Alzheimer's Study Lacks ‘Shock and Awe’ Biogen Investors Sought

(Bloomberg) -- An experimental Alzheimer’s disease drug from Biogen Inc. and Eisai Co. slowed the progression of the earliest stages of the devastating condition by 30 percent in a study, a first i...

Bloomberg Quint

Add BloombergQuint App to Home screen.